Daniel Vittecoq

Author PubWeight™ 39.93‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial. Lancet 2007 5.65
2 Telaprevir for HIV/hepatitis C virus-coinfected patients failing treatment with pegylated interferon/ribavirin (ANRS HC26 TelapreVIH): an open-label, single-arm, phase 2 trial. Clin Infect Dis 2014 1.58
3 Renal safety of tenofovir in HIV treatment-experienced patients. AIDS 2004 1.50
4 Long-term renal safety of tenofovir disoproxil fumarate in antiretroviral-naive HIV-1-infected patients. Data from a double-blind randomized active-controlled multicentre study. Nephrol Dial Transplant 2005 1.49
5 Survival and recurrence of hepatitis C after liver transplantation in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology 2008 1.47
6 Repertoire, diversity, and differentiation of specific CD8 T cells are associated with immune protection against human cytomegalovirus disease. J Exp Med 2005 1.43
7 Urolithiasis in HIV-positive patients treated with atazanavir. Clin Infect Dis 2007 1.23
8 Coronary artery disease in HIV infected patients. Intensive Care Med 2003 1.18
9 Long-term efficacy and safety of the HIV integrase inhibitor raltegravir in patients with limited treatment options in a Phase II study. J Acquir Immune Defic Syndr 2010 1.17
10 Brief report: carotid intima-media thickness in heavily pretreated HIV-infected patients. J Acquir Immune Defic Syndr 2003 1.11
11 Long-term efficacy and safety of raltegravir, etravirine, and darunavir/ritonavir in treatment-experienced patients: week 96 results from the ANRS 139 TRIO trial. J Acquir Immune Defic Syndr 2012 1.01
12 Probable intrafamily transmission of a highly virulent CTX-M-3-producing Escherichia coli belonging to the emerging phylogenetic subgroup D2 O102-ST405 clone. J Antimicrob Chemother 2010 1.00
13 Therapeutic immunization with a human immunodeficiency virus (HIV) type 1-recombinant canarypox vaccine in chronically HIV-infected patients: The Vacciter Study (ANRS 094). Vaccine 2005 0.99
14 Cytokines in HIV-associated cardiomyopathy. Int J Cardiol 2007 0.99
15 Enhanced saquinavir exposure in human immunodeficiency virus type 1-infected patients with diarrhea and/or wasting syndrome. Antimicrob Agents Chemother 2004 0.95
16 HIV-associated vascular diseases: structural and functional changes, clinical implications. Int J Cardiol 2009 0.94
17 Effect of highly active antiretroviral therapy on tacrolimus pharmacokinetics in hepatitis C virus and HIV co-infected liver transplant recipients in the ANRS HC-08 study. Clin Pharmacokinet 2007 0.92
18 Antiretroviral therapy and sustained virological response to HCV therapy are associated with slower liver fibrosis progression in HIV-HCV-coinfected patients: study from the ANRS CO 13 HEPAVIH cohort. Antivir Ther 2012 0.89
19 The French national prospective cohort of patients co-infected with HIV and HCV (ANRS CO13 HEPAVIH): early findings, 2006-2010. BMC Infect Dis 2010 0.89
20 Insulin resistance is associated with a higher risk of hepatocellular carcinoma in cirrhotic HIV/HCV-co-infected patients: results from ANRS CO13 HEPAVIH. J Hepatol 2011 0.89
21 Incidence and risk factors of thrombocytopenia in patients receiving intermittent antiretroviral therapy: a substudy of the ANRS 106-window trial. J Acquir Immune Defic Syndr 2009 0.88
22 Relationship between polymerase gamma (POLG) polymorphisms and antiretroviral therapy-induced lipodystrophy in HIV-1 infected patients: a case-control study. Curr HIV Res 2009 0.88
23 Prospective evaluation of blood concentration of mitochondrial DNA as a marker of toxicity in 157 consecutively recruited untreated or HAART-treated HIV-positive patients. Lab Invest 2004 0.88
24 Hepatitis C virus viral recurrence and liver mitochondrial damage after liver transplantation in HIV-HCV co-infected patients. J Hepatol 2005 0.83
25 Eradication of an outbreak of vancomycin-resistant Enterococcus (VRE): the cost of a failure in the systematic screening. Antimicrob Resist Infect Control 2013 0.82
26 Preservation of immune function and anti-hepatitis C virus (HCV) immune responses after liver transplantation in HIV-HCV coinfected patients (ANRS-HC08 "THEVIC" trial). J Hepatol 2009 0.81
27 Non-O:1 and non-O:139 Vibrio cholerae septicemia and pyomyositis in an immunodeficient traveler returning from Tunisia. Travel Med Infect Dis 2006 0.80
28 Cerebrovascular diseases in HIV-infected patients. Curr HIV Res 2009 0.80
29 Efficacy of etravirine for treatment of acute HIV meningoencephalitis. Clin Infect Dis 2009 0.79
30 The pavia consensus statement. AIDS 2003 0.78
31 Liver transplantation in patients with HIV infection. J Hepatol 2003 0.78
32 Therapy with boceprevir or telaprevir in HIV/hepatitis C virus co-infected patients to treat recurrence of hepatitis C virus infection after liver transplantation. AIDS 2015 0.77
33 Successful anti-hepatitis C virus therapy with telaprevir in an HIV/hepatitis C virus co-infected patient with a severe recurrence of hepatitis C virus infection on the liver graft. AIDS 2013 0.77
34 Is clinical practice concordant with the changes in guidelines for antiretroviral therapy initiation during primary and chronic HIV-1 infection? The ANRS PRIMO and COPANA cohorts. PLoS One 2013 0.77
35 [Liver transplantation for patients infected with both HIV and HCV or HIV and HBV]. Med Sci (Paris) 2007 0.76
36 Initial human herpesvirus-8 rash and multicentric Castleman disease. Clin Infect Dis 2008 0.76
37 Enfuvirtide: a safe and effective antiretroviral agent for human immunodeficiency virus-infected patients shortly after liver transplantation. Liver Transpl 2009 0.76
38 Anger and quality of life in patients co-infected with HIV and hepatitis C virus: a cross-sectional study (ANRS CO13-HEPAVIH). Eur J Gastroenterol Hepatol 2017 0.75
39 [Anti-Jo1 antibodies syndrome in an HIV-infected patient]. Ann Med Interne (Paris) 2002 0.75
40 Photo quiz. Dyspnea and fever in an allogeneic stem cell recipient. Clin Infect Dis 2015 0.75
41 [The HIV-infected traveler: infectious risks and prevention]. Presse Med 2007 0.75
42 [Therapeutic education of the patient infected with HIV]. Soins 2009 0.75
43 [Infections at risk for epidemic or biological threat. Importance of the initial management of suspect patients]. Presse Med 2011 0.75
44 Care of hepatitis C virus infection in France: modifications in three consecutive surveys between 1995 and 2010. Liver Int 2014 0.75
45 [Liver transplantation in patients with HIV: indications, limits, perspectives]. Gastroenterol Clin Biol 2003 0.75